Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Announcement today: Two plaintiff lawsuits vs LFMD have been dropped by the plaintiff law firms. This is clear evidence that the Culpeper report and the attendant law suits are baseless. LFMD and its management team are exonerated and our faith in the company is vindicated.
The announcement indicates the pleadings dropping the suits were filed around 5/20. Thus the second bogus Culpeper report is an attempt to shore up their failed effort as their assault on LFMD is destructing.
This LFMD community is dead. Reddit and Yahoo Finance have LFMD communities with almost 200 members each. Often very good info is posted.
Up more than 80% in 5 trading days. Still some shorting but seems to be much less and may be covering helping to fuel the rocket.
See beneficial ownership cvhanges above. Officers are buying!
Yesterday and so far today the short sellers seem ineffectual in holding the stock price down. Institutional ownership continues to rise. Now 60 institutions hold 34% of float and more than 20% of outstanding. This is part of the reason plus many more eyeballs on this fast grower.
LifeMD Stock Is Undervalued by Over 300%, Says Analyst
Marty Shtrubel
Marty Shtrubel
May 18, 2021, 06:22 PM
A
A
That the stock market is a forward-thinking beast is well known, but this fact has been particularly emphasized by investors during this earnings season. While many companies have delivered excellent reports, a big chunk stumbled when providing – or even deciding to not provide – the anticipated outlook. Investors have shown that what they really what to hear is not only “that was a great quarter,” but that the business has good days ahead.
As such, LifeMD (LFMD) gave investors what they wanted to hear. The telehealth provider raised full-year revenue guidance from the $85 million to $95 million range to between $90 and $100 million. The market, in return, gave a thumbs up and sent shares higher by 35% in the subsequent session.
While the outlook is rosy, the quarter’s financials were excellent too. Revenue increased by 323% year-over-year to a record $18.2 million. GAAP EPS of -$0.47 came ahead of the estimates by $0.21. Total gross margin increased by ~1,300 bps both year-over-year and sequentially to reach 82.1%, better than Wall Street’s 77% forecast, while telemedicine orders reached over 164,000, a 373% year-over-year uptick.
One disappointing metric stood out according to BTIG analyst David Larsen.
Due to higher G&A spend and operating costs, total adjusted EBITDA of ($8.9M) fell behind the Street’s ($8.3M) estimate. However, even here, Larsen finds a silver lining.
“While the higher G&A costs are disappointing, we like how sales and marketing costs in 1Q:21 increased just slightly relative to 4Q:20,” the analyst noted.
In fact, Larsen thinks there’s a lot to like about the company right now.
“We’re impressed that the annual revenue run-rate is trending at ~$73M, the subscription rate is trending at ~92%, customer retention rates are high, and we like how management is focused on growth,” Larsen said. “We like how LFMD continues to plan launches of new brands, NavaMD was launched at the end of the quarter, and the primary care platform is expected to “go-live” this coming summer. Our view is that demand for cash-pay primary care services is high, we like how LFMD might eventually accept insurance, and it seems like LFMD appreciates how important earnings are to investors.”
To this end, Larsen rates LFMD shares a Buy along with a $40 price target. Investors could be sitting on gains of 351%, should Larsen’s forecast play out as expected over the coming months. (To watch Larsen’s track record, click here)
Only one other analyst has recently chimed in with a LifeMD review, but his assessment is almost just as effusive. The additional Buy provides the stock with a Moderate Buy consensus rating, while the $37.50 average price target suggests 12-month upside of 323%. (See LFMD stock analysis on TipRanks)
LFMD signs 2 Star actresses, Kate del Castillo and Bellamy Young as Brand Ambassadors for Shapiro MD to expand women's hair loss market.
Star Actresses Kate del Castillo and Bellamy Young Partner With LifeMD as Brand Ambassadors For Shapiro MD
NEW YORK, May 18, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (“the Company”) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced partnerships with internationally acclaimed actresses Kate del Castillo and Bellamy Young. Through virtual visits with LifeMD medical professionals, they successfully treated their hair loss using Shapiro MD™ products. The partnerships announced today will include global online and offline advertising campaigns in which the stars will share their personal hair-restoration journeys and successes using Shapiro MD’s prescription and over the counter products for female hair loss.
“We are extremely pleased to have Kate and Bellamy join the LifeMD family. We are touched that they have partnered with us and agreed to share their personal experiences and successes using Shapiro MD’s telemedicine offering for hair loss,” said Dr. Anthony Puopolo, Chief Medical Officer of LifeMD. “These campaigns will spotlight the very real problem of female hair loss – which affects more than 50% of the population – to Kate and Bellamy’s large and global fan base.”
Added Kate del Castillo, “With such a busy production schedule, it’s not always possible for me to visit specialists while away on set and filming. Using Shapiro MD™ products has been incredibly convenient and effective – and has allowed me to get the care that I need.”
“Having a personal treatment plan created by a licensed medical provider has been reassuring. And the effective products that have been delivered to me by mail have really taken the complication out of seeking treatment for something so personal such as hair loss,” said Bellamy Young. “I believe a lot of people would benefit from knowing about Shapiro MD™ and its telemedicine offering for hair loss.”
Not personal. Justin does not know of the Culpeper principal. They have done this to 25 other companies in the past few years. At least one other co. recently filed a lawsuit as LFMD has done. SEC is investigating.
Good news is that 23 of the 25 other victims are selling at higher price than before the short assault.
They have to cover and soon. This is naked shorting. The corrupt broker dealers will soon become uncomfortable abetting illegal trading, especially with the lawsuit recently filed and the SEC investigation vs. Culpeper and its principal.
Welcome to the board. More insider buying now that the earnings announcement came out. The company is performing better than expected and best in industry. Shorts will have to cover. To the moon!
Lawsuit filed by LFMD vs Culper and its principal. Classic "short and distort" scheme. Jury trial demanded. This is not the first lawsuit vs Culper. This may pressure the SEC into taking action and it confirms the LFMD response as credible.
Finished after hours trading at $9,10 on 250,000 volume (huge in post mkt.)
Short activity increased substantially every day this week.
I know it is an uncomfortable time. Short sellers are engaging in an illegal practice of selling 'naked shorts' with the assistance of certain corrupt B-D's. This is bound to change and probably soon. Bloomberg just reported that Institutions own more than 25% of float. Insiders own more than 35% o total shares and have bought a net of 335,000 shares in Q1 at prices from $17 to $22. I know my network and I and the former CEO still have almost 2 mm shares that are L-T. What this means is that legal shorts must be close to exhausted and the B-D's are bound to become uncomfortable with more 'naked shorting'. Back around 4 years ago when LFMD was still known as IMMD the stock price went from $.22 to $.94 in one dat during a short squeeze. This type of move could happen again and soon.
Despite the price decline, the company's fortunes are unchanged, if anything, enhanced. Several new add-on products and new line launches occurring now. PDF Simpli growing through the roof. Launch of Concierge Telemedicine platform next month. Rising subscriptions and falling sales and marketing costs. Currently 100 inbound telemarketing seats filled. The LFMD team has done it right and built a monster marketing enterprise with great and efficacious products.
Be savvy like the institutional investors. Add to positions and buckle up for the ride.
William Blair hosted LFMD at its virtual 'Innovators in Healthcare' conference today (4/29/21) -- (SEE BULLET POINT 2 IN "OTHER THINGS TO NOTE. "SAW MEANINGFUL REDUCTIONS IN COSTS TO ACQUIRE NEW CUSTOMERS IN Q1)
LFMD was the only public company invited
Overall not much was said that was new or that wasn't already said on the BTIG or B. Riley calls last week. But I did want to let everyone know this happened because it was sort of under the radar and not publicized. I do think it's a very positive sign to see management engaging in three different investor calls over the last couple weeks, plus William Blair has a very large and reputable sell-side research business so this is great exposure to more of the institutional side of the investment community.
Few highlights:
Q: Can you talk about the competitive landscape a bit? You certainly have a handful of others in the space that you're competing with, Hims & Hers as one example, what makes you unique?
A: (Justin, and this is paraphrased) Given the size of the TAM, you're obviously going to have a lot of competition, you have a lot of smaller companies just now starting to come in and then speculation as to what Amazon's offering is going to be. But the biggest differentiator for us is the direct response nature of our business. The way I like to put it for people is our business is 80% direct response marketing and 20% branding. A lot of our peers are 80% branding and 20% direct response marketing. We like to think we have a very special and unique skillset that enables us to acquire patients at a better cost than our peers. We also continue to focus on in-licensing patented products and will continue to do this with new products that have strong intellectual property around them. We also continue to think our concierge care platform is unique, a lot of our comps are not investing to build out a virtual primary/concierge care product quite like ours.
Q: You're seeing incredible growth in the business right now, what are the headwinds to the model that could slow down this growth?
A: (Justin, paraphrased) With this type of business acquisition costs and advertising costs are always top of mind. So it's really just the overall CAC that is the major headwind to maintaining our growth numbers. As an example, sometimes we have to slow down a little bit on marketing if ad costs rise significantly at any point, but we're really in control of our growth.
Q: Are there other areas you're planning on moving into, or other future offerings?
A: (Justin, paraphrased) We're going to add more OTC products as cross sells and up sells, not really primary product launches like Rex and Shapiro but we're looking at several other markets where it's similar to ED, for example, where there are big, other conditions where people really want treatment but don't really want to go see a doctor in person for it. We have two big priorities this year. First, fully launching our concierge/primary care offering, and second, continuing to diversify the portfolio. We want to demonstrate to the market that this is a platform, and it is relevant across the entire healthcare world. Once we've done what we're doing with Rex and Shapiro with a couple other indications, that's when I feel like more people are really going to take notice that we are a platform and as a company we are more than just one single product.
Q: Is there anything else that we haven't asked that you may want to highlight for investors?
A: (Justin, paraphrased) As I've mentioned, I just want to drive home that we are a platform. We have three brands right now, with most of the telemedicine revenue coming from two (Nava only just released), but we're likely to grow into a couple hundred million dollar business from our portfolio within the next couple years. We are going to continue adding more indications to our portfolio, and with our virtual primary/concierge care offering -- this whole business model is going to change the US healthcare system for the better. It's the reason you want to be long this group of companies that are early movers and that have platforms that can make healthcare more accessible to all Americans. So many people like to say 'they are an ED company,' or 'they are a hairloss company,' but that's not what excites us. Don't get me wrong we love everything about our current business, but what really excites us here is how we are positioned to disrupt healthcare beyond just the initial indications we have in the portfolio right now. So that's what I encourage investors to think about.
Other things to note:
They're building out a mobile platform for members to navigate the entire virtual primary/concierge care service (I didn't realize they were building out a whole mobile platform as well, but maybe some of you did know that already)
Quotes from Marc reaffirming some financials: "LTV to CAC is 2x within the first 12 months, we earn back initial marketing spend in first 3 months, projected LTV to CAC exceeds 3x over 3-year period." | "Saw meaningful reductions in cost to acquire new customers in Q1, more updates will come on the Q1 earnings call in May." | "Our outlook for 2021 remains strong, we are still guiding between $85-95 million in full year revenue, or 150% annual growth, which we view as conservative."
Institutional ownership of LFMD has skyrocketed:
LFMD - LifeMD Inc Shareholders - CNNMoney.comhttps://money.cnn.com › quote › shareholders › subView...
https://money.cnn.com/quote/shareholders/shareholders.html?symb=LFMD&subView=institutional
In Q1 in addition to Millenium's huge purchase, Blackrock bought 355,000 shares, Magnus Financial 159,000 shares, Belvedere Trading 86,000 shares.
Also in Q1 insiders bought a net 335,000 shares at prices ranging from $17 to $26.
Institutional ownership has risen to more than 15%, while insiders own more than 35%
This spells danger for the short sellers, as there are a dwindling number of shares left to borrow and short. LFMD will soon surge.
Very encouraging and impressive. Reddit also has a link to this. It is great that Reddit is making people aware of LFMF. Based on LFMD's growth, pending new releases, scalable platform and comparable multiples of revenues, it should be selling at $35 now.
Two analysts reiterating buy recommendations with price targets of $35 and $40, plus a "Money Talks" endorsement with a $11 million buy in on 1.2 mm shares and 500,000 calls by Millenium Fund speaks volumes for the quality investment represented by LFMD. The short sellers are running out of shares to borrow. Its only a matter of a short time befor they see that they must cover.
Some research: Culper attacked 25 companies with their short play and bogus research. Today 23 of those companies are trading higher than before they were attacked.
Catch them in a short squeeze,... Buy several lots of 100 shares as much as you can each day. If enough of us do this, with the institutions moving in now we may be able to create a short squeeze which will amplify the upsurge.
Some research: Culper attacked 25 companies with their short play and bogus research. Today 23 of those companies are trading higher than before they were attacked.
Catch them in a short squeeze,... Buy several lots of 100 shares as much as you can each day. If enough of us do this, with the institutions moving in now we may be able to create a short squeeze which will amplify the upsurge.
LifeMD Announces Expected Record Revenue of $18.2M for Q1’21, Up 323% Vs. Q1’20, Due to Growth in Subscriptions and Patient Acquisition
More content below
LFMD
-14.94%
LifeMD, Inc.
Mon, April 19, 2021, 7:30 AM
More content below
LFMD
-14.94%
Exceeds Initial Guidance Due to Stronger Than Expected March; 41% Growth Vs. Q4‘20
NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (“the Company”) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced expected record revenue of $18.2M for Q1’21. The Company had previously guided towards revenue to be greater than $17 million (Link). However, a stronger than expected March resulted in performance exceeding that guidance. The expected quarterly revenue represents an increase of 323% year-over-year and a 41% increase compared to last quarter. Telehealth order volume grew by 373% versus the year-ago quarter, driven by both strong retention and new patient acquisition.
Justin Schreiber, CEO of LifeMD commented, “We are pleased to report another strong quarter, as revenue for Q1‘21 grew by 323% compared to revenue in Q1’20 and more than 40% quarter-over-quarter, driven by a rapidly growing recurring subscriber base and efficient acquisition spending. We onboarded a substantial number of new patients to our platform this quarter at an improved cost per acquisition (“CPA”) when compared to the prior quarter. We are excited to share more detailed metrics on our upcoming earnings call.”
Subscriptions generated 92% of revenue in Q1’21, compared to 75% in Q1’20. The increase in subscription revenue is largely due to increased sales of the company’s Shapiro MD™ hair products for men and women under a new subscription-based program, as well as continued increased subscription sales of the company’s telemedicine brand for men, Rex MD™.
LifeMD CFO, Marc Benathen, commented, “LifeMD continues to realize the significant benefits of our subscription-based business model underscored by strong patient retention and growing levels of patient acquisition. Our team has done a tremendous job of thoroughly monitoring expenses across the full brand portfolio to ensure efficient spending, while achieving a 41% increase in sequential revenue growth. As mentioned, March 2021 was a record month. We look forward to providing a complete financial and operational update on our upcoming earnings call.”
Mr. Schreiber added, “I am very proud of what our management team has accomplished in short order, and with their help, LifeMD is well-positioned to continue achieving revenue growth and further expand its footprint nationwide. In bridging the gap between technology and healthcare, we are also driving innovation, as evidenced by our patients actively choosing to enroll in our subscription-based offerings. We were also able to expand our portfolio of brand offerings at the end of the quarter when we successfully launched NavaMD™, the Company’s teledermatology brand. We are pleased by the early data we are seeing from this newly launched brand. We are also gearing up for the launch of LifeMD’s longitudinal telehealth service as part of a holistic patient-centered business model and comprehensive brand portfolio.”
Thanks for posting. This is a very detailed and complete analysis. After reading it twice I concluded that yes, the company has been conservative in its revenue estimates and had given guidance based on existing lines, and BTIG has also been conservative (as one would expect of a credible firm). Growth from existing biz will be higher than viewed and we will know early this week. Based on the company's marketing success, new product and new line launches will add significantly to the growth rate over 2021 and beyond. The company is a quality operator and takes great pains to control its operations and deliver quality at every point of contact. Hence the LifeMD concierge program will have traction and will grow nicely as a result of patient satisfaction. A 20 or 30 something can buy a cheap catastrophic policy and supplement it with LifeMD for $1200 per year and have very reasonable health risk coverage for less than $3000 vs conventional coverage of $9000. Seems like a no brainer.
Another factor is Cost of new patients. Ad cost were exceptionally high in Q4 due to the presidential election. Costs will be in line now AND the exceptional level of subscription relationships will mean a decline in the average marketing cost per shipment. Hence when Q1 comes out, expenses will look much more moderate.
Predicting the stock price is difficult due to the short situation. Will they continue to try to suppress? Will they scramble to cover in the face of high investor demand for a cheap stock? Will more institutions buy a bargain? But the trend will be up. This week's revenue announcement could be pivotal. If revenue growth accelerated from Q4 we may be off to the races.
We had a $.35 gain going until around 3:00 then shorts came in and drove price back down.
This only brings us closer to the end of available shares to short. I noticed strong buying, probably institutional judging from the size of the blocks this morning from 9:30 to 11:00 and then again from 2:00 to 2:45. They will be back tomorrow.
Yeah that's what happens during short assaults. When the stock rises suddenly there is lots for sale at much lower prices.
You are right.
The decline has stopped despite continued small short sales today. Lots of incomplete short position info out today on several financial sites. At least 30% of trades were short sales over the last 3 weeks. That means at least 6 million shares are short. More than half of the float. If many of the s/h's either placed high priced sell orders or informed their brokers that they were not to lend their shares, we are probably getting very close to exhausting supply of shares that can be borrowed.
Also institutional ownership has been rising so with continued institutional buying and current shareholders feeling more secure in averaging down their basis we will see an upswing in price and maybe a short squeeze. About 4 years ago when LFMD was IMMD we had a short squeeze where in 1 day the price went from $.22 to $.94. May it happen again...from $9.00 to $40!
You are probably right, but I hope the law firms' investigators can pierce the veils and get to these bastards.
The jerk on this platform tries to seem clueless, but he knows better. I know who he is. He once was a shareholder who had to sell some years ago before the stock price began to flourish, in order to pay some debts. He not only lost money but has never been able to build a decent position. So now his posts are simply sour grapes. I am sorry for his bad fortune, but he is simply mean spirited when he gloats over the temporary misfortune of LFMD and its shareholders. But we will be vindicated. Don't forget Gamestop!
He is a class act he called me 2 nights in a row and was actually apolegetic. He doesn't want anyone to feel let down. He takes his role very seriously. In fact, his family and friends are significantly invested. This will be back above $30 very soon.
The only clown is YOU for accepting the claims of an obviously sleazy anonymous group. The doc in question is still licensed to conduct telemedicine. He was charged with a practice, which though frowned upon , is quite common among busy docs. He signed blank prescription forms in his office. I have seen signed prescription forms on at least 2 occasions in the offices of 2 docs. So there is nothing to be concerned about here.
They use accredited physicians, licensed in all states where they practice. LFMD has 2 senior staff members overseeing medical quality and legal compliance. This management team is exceptional and does things right. WE are the victim of an unscrupulous group of scammers. Combat it by joining REddit and posting about this scam and the opportunity with LFMD
There are now at least 3 Major law firms investigating the fraudulent operations of this criminal short selling operation. I spoke with the CEO last night who called me (I have been a substantial shareholder for several years) to assure me that NONE OF THE CLAIMS were legitimate, that the company is doing very well, as reported previously, that several significant announcements are forthcoming that will clear up the truth and demonstrate the continued excellent performance of the company. In thousands and thousands of contacts with patients and customers, complaints about the subscription program are diminimus, actually in single digits.
Research Culper Research for yourselves and find out what a scam short selling program they are. They will not identify themselves or their sources and they literally hide so that they can avoid the SEC.
I joined Reddit and made a post describing the scam. We all should in order to get traction.
Culper Research is a sleazy short selling group that has made similar attempts with other rapidly rising firms. Their modus operandi is to start shorting to drive price down and then come out with a bogus research report to further push the price down so they can cover their previously developed short position. Notice the massive surge in last 2 days. Google them and you will find out that they are under investigation and have lawsuits against them They are considered fraudulent by legitimate financial firms. Cleanspark and CytoDyn are 2 recent targets of Culper Research. "Emerging Growth" Wed., April 14, has an expose on Culper Research that confirms what I have said.
Time to buy. Cause a short squeeze as these criminals attempt to cover their short positions. REMEMBER GAMESTOP!!!
Only someone totally ignorant of business would post that. Your posts continue to demonstrate your lack of knowledge. Companies in rapid growth developmental stages never pay dividends or conduct buybacks which would be an unproductive use of their cash needed to fund the rapid growth. Buybacks, further, are a bogus manipulation of the market, which only someone totally ignorant such as you would fall for. You are not a shareholder, just a griper who has missed the LFMD boat.
The recent price declines and selling is Short Selling. There is a very thin float and with so much short selling over the last 2 weeks, it will cease very soon. Shorts must cover their borrowed shares and they will fuel an upsurge. Further there is demand waiting on the sidelines as buyers are fearful of trying to catch a falling knife. Indeed, many, like myself who bought at the $20 level have gotten nicked. IMO this will reverse around mid month when Q1 revenues are announced. From what I have heard revenue growth is actually accelerating. Such positive news will spook short sellers and motivate investors.
The recent price declines and selling is Short Selling. There is a very thin float and with so much short selling over the last 2 weeks, it will cease very soon. Shorts must cover their borrowed shares and they will fuel an upsurge. Further there is demand waiting on the sidelines as buyers are fearful of trying to catch a falling knife. Indeed, many, like myself who bought in the $20 level have gotten nicked. IMO this will reverse around mid month when Q
LifeMD Launches NavaMD™ Adding Direct-to-Patient Clinical Skincare Services to its Portfolio of Personalized Telehealth Brands
More content below
LFMD
-0.75%
LifeMD, Inc.
Wed, April 7, 2021, 8:31 AM
More content below
LFMD
-0.75%
The brand launch into tele-dermatology adds further portfolio diversification into exciting and fast-growing area of patient healthcare
NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (the “Company”) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced the successful launch of NavaMD™. The NavaMD website went live at the end of the first quarter of fiscal 2021 and is the Company’s personalized tele-dermatology brand and clinic, offering services to patients across all 50 states.
Justin Schreiber, Chairman and CEO commented, “We are pleased to bring the NavaMD brand to life in 2021, as this will be LifeMD’s third successful brand launch in four years. We are an early mover in the $40 billion-dollar high growth direct-to-patient tele-dermatology space and are well-positioned to grow market share. By empowering patients seeking telehealth services, we feel that LifeMD is best positioned to actively bring about a sea change in both the convenience and accessibility by which patients receive personalized services and medications when needed. As such, we remain focused on refining customer acquisition strategies and building a de-risked brand portfolio that addresses low risk, massively underpenetrated and addressable markets such as the NavaMD clinical skincare offering.”
“By focusing on fast growing, therapeutic areas with high unmet needs, whose treatments are proven to be safe, we are creating the best runway for unrivaled growth in telehealth customer acquisition, recurring revenues and return on shareholder value,” mentioned Stefan Galluppi, Chief Technology Officer.
NavaMD’s services will be available to any patient seeking dermatology services. Service offerings include the diagnosis and treatment of prevalent skin conditions such as acne, rosacea, hyperpigmentation, signs of aging, and other prevalent skin conditions. NavaMD’s customer acquisition strategy will be primarily set to growing its female customer base, fully supported by best-in-class direct response marketing, social media, and influencer campaigns. Online medical treatment and services will be rendered through LifeMD’s network of U.S. licensed physicians, pharmacies, and, if appropriate, prescription oral and compounded topical medications to treat many common dermatological conditions. In addition to the brand’s telemedicine offerings, NavaMD’s proprietary products leverage intellectual property and proprietary formulations licensed from Restorsea, a leading medical grade skincare technology platform. NavaMD is the first external provider to offer Restorsea’s patented medical-grade over-the-counter products for treating these prevalent skin conditions.
Like other LifeMD brands, NavaMD tele-dermatology services is highly personalized, powered by a proprietary technology stack. The engagement with patients is seamless and is driven by a simple three-step customer journey consisting of:
Completing a free consultation: whereby a questionnaire and patient photo is submitted for review.
Getting prescribed a custom formulated treatment regimen: NavaMD’s licensed U.S. doctors, and clinicians then work to design a custom prescription skincare treatment. A quick and convenient checkout process powered by LifeMD’s telehealth platform fills a prescription.
The patient receives a personalized treatment by mail: LifeMD’s pharmacy services prepares and delivers a customer’s custom prescription treatment on a monthly recurring basis or as often as needed.
About LifeMD
LifeMD Launches NavaMD™ Adding Direct-to-Patient Clinical Skincare Services to its Portfolio of Personalized Telehealth Brands
More content below
LFMD
-0.75%
LifeMD, Inc.
Wed, April 7, 2021, 8:31 AM
More content below
LFMD
-0.75%
The brand launch into tele-dermatology adds further portfolio diversification into exciting and fast-growing area of patient healthcare
NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (the “Company”) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced the successful launch of NavaMD™. The NavaMD website went live at the end of the first quarter of fiscal 2021 and is the Company’s personalized tele-dermatology brand and clinic, offering services to patients across all 50 states.
Justin Schreiber, Chairman and CEO commented, “We are pleased to bring the NavaMD brand to life in 2021, as this will be LifeMD’s third successful brand launch in four years. We are an early mover in the $40 billion-dollar high growth direct-to-patient tele-dermatology space and are well-positioned to grow market share. By empowering patients seeking telehealth services, we feel that LifeMD is best positioned to actively bring about a sea change in both the convenience and accessibility by which patients receive personalized services and medications when needed. As such, we remain focused on refining customer acquisition strategies and building a de-risked brand portfolio that addresses low risk, massively underpenetrated and addressable markets such as the NavaMD clinical skincare offering.”
“By focusing on fast growing, therapeutic areas with high unmet needs, whose treatments are proven to be safe, we are creating the best runway for unrivaled growth in telehealth customer acquisition, recurring revenues and return on shareholder value,” mentioned Stefan Galluppi, Chief Technology Officer.
NavaMD’s services will be available to any patient seeking dermatology services. Service offerings include the diagnosis and treatment of prevalent skin conditions such as acne, rosacea, hyperpigmentation, signs of aging, and other prevalent skin conditions. NavaMD’s customer acquisition strategy will be primarily set to growing its female customer base, fully supported by best-in-class direct response marketing, social media, and influencer campaigns. Online medical treatment and services will be rendered through LifeMD’s network of U.S. licensed physicians, pharmacies, and, if appropriate, prescription oral and compounded topical medications to treat many common dermatological conditions. In addition to the brand’s telemedicine offerings, NavaMD’s proprietary products leverage intellectual property and proprietary formulations licensed from Restorsea, a leading medical grade skincare technology platform. NavaMD is the first external provider to offer Restorsea’s patented medical-grade over-the-counter products for treating these prevalent skin conditions.
Like other LifeMD brands, NavaMD tele-dermatology services is highly personalized, powered by a proprietary technology stack. The engagement with patients is seamless and is driven by a simple three-step customer journey consisting of:
Completing a free consultation: whereby a questionnaire and patient photo is submitted for review.
Getting prescribed a custom formulated treatment regimen: NavaMD’s licensed U.S. doctors, and clinicians then work to design a custom prescription skincare treatment. A quick and convenient checkout process powered by LifeMD’s telehealth platform fills a prescription.
The patient receives a personalized treatment by mail: LifeMD’s pharmacy services prepares and delivers a customer’s custom prescription treatment on a monthly recurring basis or as often as needed.
About LifeMD
Earnings Update: Here's Why Analysts Just Lifted Their LifeMD, Inc. (NASDAQ:LFMD) Price Target To US$37.50
More content below
Simply Wall St
Sat, April 3, 2021, 4:00 AM
There's been a notable change in appetite for LifeMD, Inc. (NASDAQ:LFMD) shares in the week since its annual report, with the stock down 10% to US$17.26. Revenues were in line with expectations, at US$37m, while statutory losses ballooned to US$4.44 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.
Check out our latest analysis for LifeMD
If you think anyone cares about your "gambling" on this stock, you are a bigger moron than we thought. We do not need luck, as it has nothing to do with the performance of LFMD. The longs have Justin and his team.
True. Growth is awesome.
FROM ANOTHER BOARD:
Let’s take a detailed peek under the hood of LifeMD:
$LFMD Revenues:
q4’19 $4M
q1’20 $4.3M (+$0.3M, 7.5%)
q2’20 $9.1M (+$4.8M, 112%)
q3’20 $11M (+$1.9M, 21%)
q4’20 $13.6M (+$2.6M, 23.6%)
q1’21 $17.1M (+$3.5M, 26.7%)
q2’21 $21.8M (+$4.7M, 27.5%)**
** = my extrapolation
And this is all while shifting the revenue mix from 68% recurring-subscription to 85% recurring-subscription, quite obviously a better model.
Removing the large one-time Covid bump from q2’20, we have revenue growth that is *accelerating*, that is to say the derivative of growth (the growth of the growth) is rising, the flywheel is working, and we can see how easily the company can get to $90M revenue with their *current* product mix. We’re still very early in the S-curve. This is incredibly powerful.
That $90M doesn’t even include the launch of NavaMD or LifeMD GP Concierge services this year. Not saying it will happen, but there is a case to be made for $100M in revenue this year.
Then, if the growth rate stopped accelerating (best to be conservative in projections), and even regressed to, let’s say, 20% Q/Q for all 4 quarters in 2022, that’s $207M in 2022 revenues. This enterprise is valued at $460M at the moment. Let that sink in.
Let’s say growth rate then fell to 10% Q/Q in 2023 (it’s harder to maintain those growth rates with size). That’s $303M revenue in ‘23. Then an anemic 5% Q/Q growth rate in ‘24 for conservatism’s sake (there are consulting firms projecting 15% annual YoY growth in telehealth through 2027).
That’s, conservatively, $370M in revenue in 2024. At 80% gross margin. That’s $300M gross profit. Holy smokes that is a lot of capital generated in a year to fuel further growth for the latter half of the decade. Or a tasty buyout by Ro or Hims at 8x Gross Profit, a $2.4B purchase (5x return from here for $LFMD shareholders).
Anyway, if you’re reading this, you’re invited to my beach house in 2026 ???? ???? Only 5 years away!
Less